canertinib has been researched along with pd 166326 in 1 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (pd 166326) | Trials (pd 166326) | Recent Studies (post-2010) (pd 166326) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 20 | 0 | 2 |
| Protein | Taxonomy | canertinib (IC50) | pd 166326 (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.0054 | |
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.006 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.093 | |
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | 0.21 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.0432 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.0781 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.636 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.0739 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.0646 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.092 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
1 other study(ies) available for canertinib and pd 166326
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |